Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Biologics CDMO Market Growth in 2025?

The market size of the biologics cdmo has experienced swift expansion in the past few years. It is projected to rise from $21.3 billion in 2024 to $24.37 billion in 2025, with a compound annual growth rate (CAGR) of 14.4%. Factors such as an increase in biologics development, cost-effectiveness and adaptability, emphasis on main skills, adherence to regulations and assurance of quality, and global expansion of pharmaceutical supply chains, have contributed to the growth in the historical period.

What Is the Forecast for the Biologics CDMO Market Size Through 2029?

Anticipated to witness swift expansion in the upcoming years, the biologics cdmo market is projected to amass a size of $42.33 billion by 2029, escalating at a compound annual growth rate (CAGR) of 14.8%. Factors propelling this growth during the forecast period include a surge in the need for biologic therapies, the rise of biosimilars and biobetters, increased funding in biomanufacturing facilities, a shift towards delegating complicated procedures, emphasis on resilient supply chain and risk reduction, regulatory synchronization, and fast-tracked approvals. The forecast period is also expected to witness dominant trends like broadening of capacities to proffer comprehensive solutions, acceptance of single-use technologies, incorporation of incessant manufacturing methods, and the rise of niche CDMOs.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp

What are the Key Market Players in Biologics CDMO Market and How They’re Evolving?

Major companies operating in the biologics CDMO market are AbbVie Inc., Thermo Fisher Scientific Inc., Novartis AG, Evonik Industries AG, Sandoz International GmbH, ICON PLC, Grifols SA, Lonza Group Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., JSR Corp., Parexel International Corporation, WuXi Biologics (Cayman) Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., Rentschler Biopharma SE, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Binex Co. Ltd., Bora Pharmaceuticals Co. Ltd, 3P Biopharmaceuticals s.l.u, JRS Pharma LP, J Rettenmaier and SOHNE GmbH and Co KG, Kemwell Biopharma Pvt. Ltd., Cytovance Biologics, AGC Biologics, Shenzhen Hepalink Pharmaceutical Co. Ltd.

What Are the Primary Growth Drivers in the Biologics CDMO Market?

The boost in the need for cellular and gene-based therapies is projected to fuel the expansion of the biologic CDMO sector in the future. Both, cell and gene therapies adopt novel medical strategies that use living cells or genetic material to tackle the root causes of illnesses on a cellular or genetic scale. These therapies serve as promising treatment options for conditions that are hard to treat or untreatable with conventional pharmaceuticals. The increased demand for these therapies can be attributed to their potential to offer cutting-edge treatments for diseases by targeting the genetic or cellular origins. Biologic CDMOs aid in the safe and efficient production of cell and gene therapies as they specialize in handling live cells, viral vectors, and genetic materials. They also help biopharmaceutical firms to cope with regulatory demands and technical hurdles thus, allowing a smoother transition from research to clinical application. For example, The American Society of Gene & Cell Therapy (ASGCT) reported in January 2023 that the gene, cell, and RNA therapy pipeline experienced a growth rate of 7% in 2022, reaching a grand total of 3,726 therapies being developed. Out of these, gene therapies account for 55%, whilst non-genetically modified cell therapies equate to 22%, and RNA therapies make up 23%. Therefore, the growing demand for cellular and genetic therapies is actually catalyzing the biologic CDMO market’s expansion.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=14056&type=smp

What Are the Leading Segments in the Global Biologics CDMO Industry?

The biologics cdmo market covered in this report is segmented –

1) By Cell Type: Mammalian, Non-Mammalian

2) By Product Type: Biologics, Biosimilars

Subsegments:

1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells

2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells

What Are the Key Market Trends in the Biologics CDMO Industry?

Leading firms in the biologics CDMO market are pioneering technological advancements like novel cell lines to bolster the evolution and manufacturing competence of biopharmaceuticals. Such technology yields therapeutic antibodies with heightened potency, thereby addressing challenges in immunotherapy research and development. For example, Lonza Group, a Swiss company specializing in the pharmaceutical and biotechnology realms, unveiled GS Effex cell lines in November 2023. These are engineered to generate antibodies that are entirely devoid of fucose, a type of sugar molecule and exhibit amplified potency without sacrificing other performance aspects. This technology solves immunotherapy research and development difficulties concerning the demand for more potent antibody therapeutics. The GS Effex cell line is stable, scalable, and prolific, offering a resolution for therapeutic development from the stage of discovery through to commercial production.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

What Is the Regional Outlook for the Biologics CDMO Market?

North America was the largest region in the biologics CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14056

This Report Delivers Insight On:

1. How big is the biologics cdmo market, and how is it changing globally?

2. Who are the major companies in the biologics cdmo market, and how are they performing?

3. What are the key opportunities and risks in the biologics cdmo market right now?

4. Which products or customer segments are growing the most in the biologics cdmo market?

5. What factors are helping or slowing down the growth of the biologics cdmo market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model